CME Group (CME)
NASDAQFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-07
$240.75+2.55%
Close 2026-07-07 · 1-day change
Reading CME? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CME free→NASDAQFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-07
Reading CME? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CME free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in deceleration. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 8% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCME's growth depends on expanding its product offerings and market access. The company plans to launch single stock futures on July 27. Revenue grew 14% year over year, and the last quarter met expectations. CME trades at 20× P/E versus a peer median of 17×. The price reflects less growth than expected, indicating modest expectations. If CME cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 7% above where it trades.
Trailing returns as of 2026-07-07. CME is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering CME (as of Jul 2026).
Based on 5 Wall Street analysts offering 12-month price targets for CME in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. Current price $240.75. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Advances: Expand product offerings and market access
New product offering enhances market access and growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $240.75
The last 12 months of price, then the range of analyst 12-month targets from today’s $240.75.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand product offerings and market access
New product offerings enhance growth potential in derivatives.
Advances: Expand product offerings and market access
Launch of new product expands offerings and market access.
Advances: Expand product offerings and market access
New CEO aligns with expansion of product offerings.
Advances: Expand product offerings and market access
New futures launch expands product offerings and market access.
CEO succession may impact management's strategic direction.
Legal action may delay product offerings and market access.
Legal action may hinder market access and product expansion.